Wire · opportunities
Novo's CagriSema delivers about 21% weight loss at lower doses
◆ Sectors
Health
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 16 November 2026 · Fusion42 review
Novo Nordisk’s Phase 3 trial shows their CagriSema drug achieves about 21% weight loss at doses lower than the 2.4 mg dosage submitted for FDA approval, with a decision expected in 2026.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You must adjust your weight management product roadmaps as lower dose CagriSema shows strong results ahead of FDA approval, setting a new bar for efficacy and dosing strategy.
◆ Coverage
1 source · 16 Nov 2026
◆ Related on Wire
◆ Topics
Healthweight-losspharmaclinical-trialFDA-approvalbiotech